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Abstract Lack of differentiated functions of the
tissue of origin in tissue culture thought to be due to
dedifferentiation was shown to be due to selective
overgrowth of ﬁbroblasts. Enrichment culture tech-
niques, (alternate animal and culture passage),
designed to give the functionally differentiated cells
selective advantage over the ﬁbroblasts resulted in a
large number of functionally differentiated clonal
strains. Thus the dogma of dedifferentiation was
destroyed. It is proposed to substitute the dedifferen-
tiation hypothesis with the hypothesis that cells in
culture accurately represent cells in vivo without the
complex in vivo environment. With the development
of hormonally deﬁned media, combined with func-
tionally differentiated clonal cell lines, the potential
of tissue culture studies is greatly augmented. Hor-
monal responses and dependencies can be discovered
in culture and the discovery of dependencies of
cancer cells has led to a new rationale for therapy.
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It is an honor and great privilege to deliver the
Murakami Memorial lecture. Hiroki Murakami spent
2 years in my laboratory where he learned of the
great potential of tissue culture, and was inspired to
form a Japanese Society that could exploit its many
possibilities. I helped Hiroki overcome the opposition
of existing societies by bringing distinguished Amer-
ican lecturers to the ﬁrst JAACT meeting. The subject
of papers presented at this meeting represent the
important role of cell technology in solving human
health problems. Hiroki would be pleased at the
evolution of JAACT and the impressive prospects for
its future. I believe JAACT will continue to be a great
force in the development of cell science in Japan.
My objective in 1957 when I ﬁrst entered the ﬁeld
of tissue culture was to study the basic element of the
animal, the cell, in isolated, controlled conditions,
tissue culture, to learn the details of animal physiol-
ogy. The trouble with this simple idea in 1957 was
that animal cell cultures rarely exhibited the differ-
entiated properties of the tissue of origin. It was
universally believed that cells in culture underwent
dedifferentiation to become a common cell culture
type. In other words, cells in culture were different
from cells in the animal. It was crucial for tissue
culture to determine if this was true. In 1960, we did
the only experiment ever performed to determine if
the lack of differentiated properties in culture was
due to dedifferentiation or selection of a minority cell
type in the inoculum, the connective tissue ﬁbroblast.
In this experiment freshly isolated mouse liver tissue
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untreated, the second portion was treated with
speciﬁc anti-liver parenchyma antisera and comple-
ment, and the third portion was treated with speciﬁc
anti-ﬁbroblast antisera and complement. Treatment
with anti-liver parenchyma antisera and complement
resulted in a great amount of complement ﬁxation.
After brief treatment the antisera and complement
were washed away and the inoculum plated in
culture. No effect of this treatment was noted, as
the subsequent growth was equivalent to the
untreated control. When the inoculum was treated
with anti-ﬁbroblast antiserum, complement ﬁxation
was negligible as very few ﬁbroblast were present in
the inoculum, but subsequent growth was completely
inhibited. The lack of liver properties in culture was
not due to dedifferentiation but to selective over
growth of ﬁbroblasts. This should have settled the
matter, but publication of this paper (Sato et al. 1960)
brought me a great deal of abuse. Members of the
tissue culture association rhetorically announced that
they would buy me a microscope so I could see liver
cells turn into ﬁbroblasts, and the American Cancer
Society in response to my application for a grant
wrote me that I should never again apply to the
society for a grant. Often scientists ﬁnd it difﬁcult to
accept the demise of a long standing notion which
they have come to accept as fact even when presented
with data demonstrating that this ‘‘fact’’ cannot be
true. Now 45 years after my controversial publication
young scientists are unaware that dedifferentiation
was once dogma.
The next step was to develop enrichment culture
techniques which would give the differentiated cells
some selective advantage over ﬁbroblasts. This was
accomplished by using functionally differentiated
animal tumors and alternately passaging these tumors
through culture and animal. The rationale was that
each passage through culture would select culture
hardy variants of the functionally differentiated
tumor cells and these would be able to compete with
ﬁbroblasts in culture. In this way we established
steroid secreting and ACTH responsive adrenal tumor
cells and ACTH secreting pituitary tumor cells
(Buonassisi et al. 1962). By this method, within
10 years we had established functional clonal lines of
steroid secreting adrenal cells, ACTH secreting
pituitary cells, growth hormone secreting pituitary
cells, antigen speciﬁc glial cells, neuroeffector
synthesizing neuroblastoma cells, differentiating ter-
atoma cells, pigmented melanoma cells, androgen
secreting testicular cells etc. Thus the dedifferentia-
tion hypothesis was destroyed. Fresney in his book on
cell culture says the dedifferentiation hypothesis died
by itself. I believe his thinking is limited like the
early tissue culture establishment that thought I
should get a microscope so I could see liver cells
change into ﬁbroblasts. Not only does dedifferentia-
tion not occur, but I would also like to put forward
the hypothesis that cells in culture accurately repre-
sent cells in the animal body, and that discoveries
made on cells in culture are directly related to animal
physiology.
At this point it was pointed out to me by Kiyoshi
Ueda, a post-doctoral fellow in the lab, that no cell
cultures existed whose proliferation was driven by
hormones, as were cells in the animal. We set out to
develop cells in culture whose proliferation would be
driven by hormones by following the procedure of
Biskind and Biskind (1944). They implanted rat
ovary tissue in the spleen of ovariectomized rats. The
spleen is drained by the hepatic portal vein and any
steroids secreted by the implant are destroyed by the
liver. The pituitary sensing a deﬁciency of steroids
secretes gonadotrophins causing the ovarian implant
to grow. We established such ovarian cells in culture
and their growth was dependent on the addition of
some crude NIH Luteinizing Hormone. At this point
the human factor began to complicate things. We got
pure LH from Dennis Gospodarawicz and it was
inactive. He wanted to purify the new factor using our
ovarian cells, but I had a Japanese, protein chemist,
post-doctoral fellow coming and I wanted him to
purify the factor. Another post-doctoral fellow in my
laboratory found that the crude LH stimulated 3T3
cells to grow and he wanted credit for discovering the
new factor, so secretly he was meeting with Dennis to
work with him. Meanwhile my grant was turned
down on the grounds that pure luteinizing hormone
was not active and a subsequent grant that showed
that hormones could replace serum was turned down
on the grounds that just because one cell could have
its serum replaced by hormones did not mean that this
would be true for all cells. My interpretation was that
the person who turned down my grants had previ-
ously worked in my lab and wanted to be known as
the person who brought cell culture to endocrinology.
It was simply a matter of poisonous competition, and
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hormonal replacement of serum would not be funded.
Thus my lab which had made important innovative
discoveries was in ﬁnancial trouble.
About this time, I went on sabbatical leave to the
Basel Institute of Immunology because I had been an
admirer of Niels Jerne from my graduate school days
at Cal Tech. During my stay in Basel, I was asked to
write an essay on what I thought the function of
serum was in tissue culture (Sato 1975). In this essay,
I proposed that the function of serum was to provide
hormones. A year later, Izumi Hayashi in my lab
showed this was true for GH3 cells that produced
growth hormone (Hayashi and Sato 1976). This
principle has proven to be generally valid and
represents a key advance in endocrinology, and yet
the Endocrine society has not seen ﬁt to devote a
session to this subject. The culture approach uncovers
many more responses by cell types to hormones and
uncovers hitherto unknown hormones (growth fac-
tors). The responses found in culture should be tested
in the animal and the so-called growth factors should
be tested in vivo. This approach should reveal
hitherto unknown complexities, which are necessary
to explain necessary subtle control mechanisms.
Autocrine hormones are discovered by the culture
approach. The Cancer society has not devoted a
session to hormonally deﬁned media although it will
be central to developing therapies in the future. The
cultures of liver parenchyma and embryonic stem
cells have been difﬁcult in the past (Martin 1981;
Ichihara et al. 1980). With the development of
hormonally deﬁned media, ﬁbroblastic overgrowth
is eliminated and the media could be designed to
support only the growth of the desired cell. Estab-
lishment of cell types previously considered difﬁcult
should become routine.
The discovery of hormonally derived media caused
me to think about hormonal requirements of cancer
cells and possible approaches to therapy (Sato 1980;
1981). In these articles, I mused about hormonal
dependencies of cancer discovered in culture and
proposed possible therapies by blocking the hormones
by antibodies to their receptors. Normal tissues
deprived of their trophic hormones shrink, but after
the hormone is restored the normal tissue regains its
original size. I believe that a cancer cannot survive
deprivation of its hormone. I draw this conclusion
from analogy with the experiment of Francoise Kelly
(Kelly and Sambrook 1973). She treated 3T3 and SV
transformed 3T3 (SV3T3) with cytochalasin B, which
blocks cell division. Normal 3T3 when treated with
cytochalasin makes a binucleate cell and then stops
nuclear division. When cytochalasin is removed the
binucleate divides to form two mononucleate cells
and then divides normally. When SV3T3 is treated
with cytochalasin, the cell cannot divide but the nuclei
continue to divide to form a multinucleate cell, and
when the cytochalasin is removed the multinucleate is
non-viable. I believe that this is a general principal.
When one process is inhibited the normal cell can
coordinately inhibit other processes that if allowed to
continue would result in a non-viable situation. The
cancer cell cannot do this. Therefore, I believed if we
could inhibit one hormone dependent process in a
cancer cell that this would result in the death of the
cancer cell. In time, I believe that this will become a
general principle concerning the vulnerability of
cancer cells. I thought to make anti-EGF-receptor
antibody because I knew of long acting thyroid factor
which was an antibody to the TSH receptor so that
antibodies to hormone receptors were possible, and
the EGF receptor had been puriﬁed by Stanely Cohen
(Cohen et al. 1980). The work was done by my son,
Denry Sato, and a post-doctoral fellow, Tomoyuki
Kawamoto. The concept of hormone therapy was well
formulated and the plan of work was well thought out
when John Mendelsohn became a self-invited guest in
our laboratory observing the work with interest. The
antibody could block growth in culture of A431 cells
in culture and block the formation of tumors in nude
mice. This is conﬁrmation that cells in culture
accurately represent cells in vivo. At this point, I
was busy taking over the direction of an Institute in
Lake Placid NY. Unknown to us John Mendelsohn got
a company to commercialize the product and develop
a humanized version of the antibody for human
therapy. This has proven to be successful and now is
the biggest money earner for the University of
California at San Diego. The development of a
monoclonal antibody therapy to cancer depends on a
long series of experiments. First of all dedifferentia-
tion did not occur. Clonal lines of functionally
differentiated cells had to be grown which showed
that cells in culture accurately represented cells in the
animal. The hormonal requirements of cells (tumor)
had to be determined. Monoclonal antibodies to a
hormone receptor had to be produced. These
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show that the tumors in nude mice were also killed.
Fortunately, I had established a nude mouse colony
with great effort in my laboratory (Masui et al. 1981).
The general validity of this approach is demonstrated
by the remarkable work of Ginette Serrero on breast
cancer, which began in the W. Alton Jones Cell Center
and continues at A. and G. Pharmaceutical Corp.
(Serrero 2003). In culture, it was discovered that
pituitary cells that secrete growth hormone respond to
TRH by secreting prolactin. In animals it was shown
that TRH causes the secretion of prolactin (Tashjian Jr
1979). In the future, I expect many more hormonal
responses to be discovered in tissue culture.
At Lake Placid, I tried to form an Institute, the W.
Alton Jones Cell Science Center, that develops and
supports young scientist. The model, I had in mind
was the old Kaiser Wilhelm Institutes. The scientists
were freed from the poisonous need to compete for
credit and ﬁnancial support. They worked for the love
of science and the understanding that one of the
moral objectives was to improve the human condi-
tion. To this end, Wally McKeehan and I formed
Upstate Biotechnology to support the institute. This
company was recently sold for 200 million dollars. I
almost succeeded. The Jones Foundation closed the
scientiﬁc center and kept the company. However, my
vision has been instilled in many of my students, and
someday they will form the ideal, self supporting
institute where scientists work for the love of science
and where advances in biology will be made that
better the human condition.
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